Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
about
Aldosterone antagonists for preventing the progression of chronic kidney diseaseAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseaseAldosterone antagonists for preventing the progression of chronic kidney diseaseAldosterone antagonists for preventing the progression of chronic kidney diseaseRenal outcome in adults with renal insufficiency and irregular asymmetric kidneysDoes the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review.Sickle cell disease in childrenAntihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone systemDietary protein restriction and preservation of kidney function in chronic kidney diseaseStop chronic kidney disease progression: Time is approachingEvidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature--preventable causes of AKI and SORO-ESRD--a call for re-engineering of nephrology practice paradigms.Mechanisms underlying renoprotection during renin-angiotensin system blockade.Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.Low documentation of chronic kidney disease among high-risk patients in a managed care population: a retrospective cohort studyNephropathy in type 2 diabetes.Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.Proteinuria, (99m) Tc-DTPA Scintigraphy, Creatinine-, Cystatin- and Combined-Based Equations in the Assessment of Chronic Kidney Disease.Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.Kidney dysfunction in patients with pulmonary arterial hypertensionStem cell-based cell therapy for glomerulonephritisAngiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial.Evolution of drugs that preserve renal function.Renal protective potential of antihypertensive drugs.Is there a role for endothelin antagonists in diabetic renal disease?Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study.Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature.Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease.The urgent call of albuminuria/proteinuria. Heeding its significance in early detection of kidney disease.Reduced incidence of end stage renal disease among the elderly in Denmark: an observational study.Safety of ACE inhibitor therapies in patients with chronic kidney disease.Influence of progressive renal dysfunction in chronic heart failure.Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension.Eplerenone--a novel selective aldosterone blocker.Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
P2860
Q24194979-373B40F0-9712-412D-BE5F-3520227B4F21Q24235834-A511363F-D8AF-447C-8D2B-7512BE6F52F5Q24239909-BC5518EF-3E4C-473C-8250-16185201A035Q24243615-188A012C-785A-4FDA-8AB2-DFB937E0B202Q24791709-EF2C0E3C-D1A2-4B10-9AFB-722FF934660AQ24816744-C58B9DC4-4FEB-4BC2-B21E-452C48180090Q26864582-B405DDF0-81A0-46BF-9C28-8D6AA70D36FEQ26865691-9F483D27-1DE1-4B61-80D9-26C42B2C3E6DQ27027659-21A488CF-5470-477A-9697-27D254A2D559Q28078020-9CD5C675-001A-4E70-B843-2E3BB2ACE131Q30431327-1BAA1423-2B09-419B-BF31-91B4796769E2Q32032668-AF54F5C5-4FBA-4982-9AC9-B2D4B59A0697Q33291468-653CB33E-595B-429F-A231-E7B7F62A73B7Q33325660-A0B78463-4A24-4B41-B943-775F92DA6A62Q33503903-623A5A06-E564-4640-9EE0-74EE775F27E4Q33542374-0AC46A94-88AD-4B54-A36D-33BB99C584CAQ33561456-DD9AFBF5-8790-491D-A152-99EC3C9DAE7FQ33710875-974234FB-F4C3-4D2F-A0CF-EA4F23F5E3BDQ33737225-FAEC2552-9854-4774-9BAC-C34751D2FF54Q33738621-B5F32E66-4990-4B6A-9AC6-8CF2500C2183Q33805069-078CAAE9-2D2E-4500-8B1A-88D5D4C39F9DQ33836604-C4A58F99-E8A2-4196-A470-E8CDAF164F65Q33900224-CB2847C1-5EA4-4678-83EC-EC16169C3377Q34024129-F1B3A15D-FF6C-4925-89BC-1D1BE658F000Q34075168-16A5EE1D-1366-46B1-A2FD-F904436ECF16Q34163153-44F31074-A24C-4361-A4BF-32C54634FE6CQ34185922-9CB07F6F-9E4A-44AE-A155-06F5381E4B31Q34244029-75399263-D5F9-4625-A1E2-F7497EE37781Q34299778-887C3135-9B2A-4EC0-B96D-A578FC1155EAQ34391982-EA6C4CD6-AB09-4AB7-8471-7F729C54BA82Q34417448-315D3AFC-9423-4432-BFEC-01FD43E88DB2Q34433011-F2BF9E30-ACE0-4B2A-8AC6-0E320BECFD3AQ34434606-8B126066-5FA6-43C9-9C40-DF6DED4065CAQ34604651-CCF74C0D-4DA6-4DC6-95A4-162E2A8D8929Q34629660-4822F296-8519-447D-B325-9174B96F521FQ34658876-FCDAA9D0-93C5-4F31-A34C-257E3EE4D850Q34754166-C255028B-5F8C-449E-89D4-CFF8C2902316Q34849534-6EE0C324-9E2C-4A06-8486-600D0AFFFF57Q34874363-122BE146-535F-41D3-86F0-313FA494278FQ34945403-F04A188C-8F0C-460D-8F53-C87728F4F701
P2860
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
description
article publié dans la revue scientifique The Lancet
@fr
im Juni 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 1997
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Randomised placebo-controlled ...... uric, non-diabetic nephropathy
@en
Randomised placebo-controlled ...... uric, non-diabetic nephropathy
@nl
type
label
Randomised placebo-controlled ...... uric, non-diabetic nephropathy
@en
Randomised placebo-controlled ...... uric, non-diabetic nephropathy
@nl
prefLabel
Randomised placebo-controlled ...... uric, non-diabetic nephropathy
@en
Randomised placebo-controlled ...... uric, non-diabetic nephropathy
@nl
P1433
P1476
Randomised placebo-controlled ...... uric, non-diabetic nephropathy
@en
P304
P356
10.1016/S0140-6736(96)11445-8
P407
P577
1997-06-01T00:00:00Z